Home > Resources > Whitepapers > Small Molecule Apis Made with Compelling Science

Research, Medical

Small Molecule Apis Made with Compelling Science

July 17, 2023

As your API demand grows, we grow with you. While we can manufacture volumes in metric tons, we can also go small. If you have a chemistry-based compound and need smaller batches for clinical or commercial use, we can offer the quantities you need at our cGMP small-scale/pilot facilities until you’re ready for full-scale manufacturing.

Spotlight

Eurofins Genomics

Eurofins Genomics was founded in 1990 and is part of the Eurofins Scientific Group, a Life Science Company with laboratories in 48 countries and 48,000 employees. We are an international provider of genomic services around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis.

OTHER WHITEPAPERS

Lipid Nanoparticle and Liposome

whitePaper | September 12, 2022

Lipid nanoparticles (LNPs) and liposomes are variations of lipid-based drug carriers differing in their internal structure.

Accurate and reliable cell counting using holographic microscopy and machine learning algorithms

whitePaper | August 11, 2022

Reliable and accurate cell counts are crucial for many different purposes such as the maintenance of cell cultures in biological research or in-process controls in industrial bioprocessing.

HFPP Fraud, Waste, and Abuse in the Context of COVID-19

whitePaper | January 24, 2022

Since early 2020, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome.

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

Bispecific Antibodies - CMC Considerations

whitePaper | December 16, 2022

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

Lipid Nanoparticle and Liposome

whitePaper | September 12, 2022

Lipid nanoparticles (LNPs) and liposomes are variations of lipid-based drug carriers differing in their internal structure.

Accurate and reliable cell counting using holographic microscopy and machine learning algorithms

whitePaper | August 11, 2022

Reliable and accurate cell counts are crucial for many different purposes such as the maintenance of cell cultures in biological research or in-process controls in industrial bioprocessing.

HFPP Fraud, Waste, and Abuse in the Context of COVID-19

whitePaper | January 24, 2022

Since early 2020, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome.

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential
to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying
dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial
improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic
objective. Some of these indications may require more than one dose to achieve continued symptom relief
and scientists and companies are working on technologies that will enable the use of a repeat dose.

Bispecific Antibodies - CMC Considerations

whitePaper | December 16, 2022

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

More Whitepapers

Research, Medical

Small Molecule Apis Made with Compelling Science

Spotlight

Eurofins Genomics

OTHER WHITEPAPERS

Lipid Nanoparticle and Liposome

Accurate and reliable cell counting using holographic microscopy and machine learning algorithms

HFPP Fraud, Waste, and Abuse in the Context of COVID-19

Are Nitrosamines aConcern for BiologicManufacturers?

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

Bispecific Antibodies - CMC Considerations

Lipid Nanoparticle and Liposome

Accurate and reliable cell counting using holographic microscopy and machine learning algorithms

HFPP Fraud, Waste, and Abuse in the Context of COVID-19

Are Nitrosamines aConcern for BiologicManufacturers?

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

Bispecific Antibodies - CMC Considerations

Spotlight

Eurofins Genomics

Events